Statin use in veterans undergoing cardiovascular implantable electronic device placement was associated with a 66% reduced risk of subsequent device infection (OR 0.34; 95% CI 0.2-0.59; P<0.001).
Cohort (n=18,970)
Yes
Does statin use reduce the risk of cardiovascular implantable electronic device infection in veterans undergoing CIED placement?
Statin use is associated with a 66% reduction in the risk of cardiovascular implantable electronic device infection among veterans.
Effect estimate: OR 0.34 (95% CI 0.2-0.59)
p-value: p=< 0.001
BACKGROUND: The rate of cardiovascular implantable electronic device infection (CIEDI) has increased, despite the use of perioperative antibiotics at the time of device placement or revision. This is due, in part, to the presence of multiple comorbid conditions in an elderly population, in general, who require CIED. Statins may have an antibacterial effect, although there is currently no evidence that the likelihood of CIEDI has been impacted by statin use. METHODS: A retrospective cohort study was performed to assess whether statins are associated with a reduced risk of CIEDI. The VA Informatics and Computing Infrastructure (VINCI) database, which includes all veterans who underwent CIED placement between 2008 and 2015, was used. A logistic regression model was constructed to estimate the adjusted risk of CIEDI among patients who were receiving statins after adjusting for confounding factors. RESULTS: Overall, 18,970 CIED procedures were included, and 98% of them were performed in men with a mean age of 71 ± 11 years. The rate of diabetes mellitus, heart failure, advanced chronic kidney diseases, CIEDI, positive methicillin-resistant Staphylococcus aureus nasal colonization, and statin use were 23%, 15.7%, 3.3%, 1.14%, 12.6%, and 56%, respectively. The logistic regression analysis showed that statins were significantly associated with a reduced risk of CIEDI; after controlling for other effects, the reduction was 66% (odds ratio 0.34 0.2-0.59, P-value < 0.001). The effect of statins was confirmed by propensity score analysis. CONCLUSIONS: Our study showed that among patients receiving statins who had undergone CIED placement, there was a 66% reduction in subsequent CIEDI.
Alzahrani et al. (Wed,) conducted a cohort in Cardiovascular implantable electronic device infection (n=18,970). Statins vs. No statin use was evaluated on Cardiovascular implantable electronic device infection (CIEDI) (OR 0.34, 95% CI 0.2-0.59, p=< 0.001). Statin use in veterans undergoing cardiovascular implantable electronic device placement was associated with a 66% reduced risk of subsequent device infection (OR 0.34; 95% CI 0.2-0.59; P<0.001).